Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:07 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 65 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Ranolazine Clear all

Conditions: Diabetes Mellitus, Type 2
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 9
States / cities: Escondido, California • Los Angeles, California • Miami, Florida + 6 more

Conditions: Myocardial Ischemia, Coronary Artery Disease, Arteriosclerosis, Chronic Stable Angina
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: East Carolina University; Other
Eligibility: 21 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Greenville, North Carolina

Conditions: Ranolazine, Diastolic Heart Failure, Tissue Doppler Ultrasound, Echocardiography
Interventions: ranolazine; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: San Diego, California

Conditions: Atrial Fibrillation, Heart Failure
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Murray, Utah

Conditions: Myocardial Perfusion Imaging, Myocardial Ischemia
Interventions: Ranolazine, Placebo to match ranolazine, SPECT MPI, Exercise; Drug · Procedure · Behavioral
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 26
States / cities: Birmingham, Alabama • Imperial, California • Lincoln, California + 23 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Metformin, Ranolazine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Arrhythmia
Interventions: Amiodarone Plus Ranolazine, Amiodarone with Placebo; Drug
Lead sponsor: Hartford Hospital; Other
Eligibility: Not listed
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Adenocarcinoma of the Prostate, Bone Metastases, Soft Tissue Metastases, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions: Ranolazine; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 19 Years and older · Male only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Diabetes, Type I, Diabetes, Type II, Angina, Coronary Artery Disease
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 90 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Heart Failure With Preserved Ejection Fraction
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: San Diego, California

Conditions: Microvascular Coronary Dysfunction (MCD)
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 2
States / cities: Los Angeles, California • Gainesville, Florida

Conditions: Angina
Interventions: Ranolazine, Sugar pill; Drug
Lead sponsor: North Florida Foundation for Research and Education; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Coronary Artery Disease, Angina, Metabolic Syndrome
Interventions: Ranolazine; Drug
Lead sponsor: Atlanta Heart Specialists, LLC; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Cumming, Georgia • Tucker, Georgia

Conditions: Type 2 Diabetes Mellitus
Interventions: Ranolazine, Placebo, Diet, Exercise; Drug · Behavioral
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 465 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 57
States / cities: Glendale, Arizona • Phoenix, Arizona • Tucson, Arizona + 49 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: Swathy Chandrashekhar, MBBS; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 6
States / cities: San Francisco, California • Jacksonville, Florida • Fairway, Kansas + 3 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 72 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Chronic Stable Angina, Coronary Artery Disease, Atrial Fibrillation, Ventricular Tachycardia
Interventions: ranolazine, placebo; Drug
Lead sponsor: Cardiovascular Consultants of Nevada; Other
Eligibility: 35 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Henderson, Nevada • Las Vegas, Nevada

Conditions: Peripheral Arterial Disease
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: Corewell Health East; Other
Eligibility: 40 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Myocardial Ischemia
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Type 2 Diabetes Mellitus
Interventions: Ranolazine, Placebo, Exenatide; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 3
States / cities: Chula Vista, California • Miami, Florida • Orlando, Florida

Conditions: Ventricular Premature Complexes, Myocardial Ischemia
Interventions: ranolazine; Drug
Lead sponsor: Kent Hospital, Rhode Island; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Warwick, Rhode Island

Conditions: Type 2 Diabetes Mellitus
Interventions: Ranolazine, Placebo to match ranolazine, Metformin, Placebo to match metformin, Diet, Exercise; Drug · Behavioral
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 442 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 60
States / cities: Gulf Shores, Alabama • Little Rock, Alaska • Chandler, Arizona + 53 more

Conditions: Angina Pectoris, Coronary Artery Disease, Type 2 Diabetes Mellitus
Interventions: Ranolazine, Ranolazine placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 949 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 20
States / cities: Little Rock, Arkansas • Merced, California • Moreno Valley, California + 17 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Metformin, Ranolazine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: San Antonio, Texas

Search by objective public record fields.

Exploratory Study to Access the Metabolic Effects of Ranolazine in Subjects With Type 2 Diabetes Mellitus When Added to Ongoing Non-insulin Antidiabetic Therapy

Efficacy of Ranolazine in Patients With Chronic Total Occlusions of Coronary Arteries

Effect of Ranolazine on Echocardiographic Indices of Diastolic Dysfunction

The Use of Ranolazine for Atrial Fibrillation and Diastolic Heart Failure

Effect of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging

Single Cohort, 2-Period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine 500 mg

The Adjunctive Ventricular Arrhythmia Suppression Trial (AVAST) Pilot

A Pilot Study to Enhance F18 FDG-PET Imaging of Prostate Cancers With the Metabolic Inhibitor Ranolazine

Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Diabetic Patients and CAD

The Effects of Ranolazine on Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction

Treatment With Ranolazine in Microvascular Coronary Dysfunction (MCD): Impact on Angina Myocardial Ischemia

Ranolazine Among Unrevascularized Chronic Stable Angina Patients

Ranolazine, Ethnicity and the Metabolic Syndrome

Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus

A Study of Ranolazine in ALS

A Study of Ranolazine Acute Administration and Short Term Administration in Pulmonary Arterial Hypertension

Safety of Amiodarone and Ranolazine Together in Patients With Angina

Supervised Treadmill Exercise and Ranolazine for Intermittent Claudication of Lower Extremities

Microvascular Coronary Disease In Women: Impact Of Ranolazine

A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.

Ranolazine Mediated PVC Reduction in Ischemic Heart Disease

A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone

Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina

Single Cohort 4-period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine